Hepatitis C virus to hepatocellular carcinoma

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Jahan, Shah ^a   Ashfaq, Usman A ^b   Qasim, Muhammad ^b   Khaliq, Saba ^a   Saleem, Muhammad ^c   Afzal, Nadeem ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Government College University (GCU)   (Pakistan)

^c UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYCLOOXYGENASE 2; CYTOKINE; HOST FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; PROTEIN KINASE B; VASCULOTROPIN; VIRUS PROTEIN;

ANGIOGENESIS; APOPTOSIS; CELL PROLIFERATION; CYTOKINE RELEASE; DISEASE COURSE; FATTY LIVER; GENETIC TRANSCRIPTION; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VIRUS LOAD; VIRUS NUCLEOCAPSID;

EID: 84856287530     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-2     Document Type: Review

References (79)

1. Course and outcome of hepatitis C. Hoofnagle JH, Hepatology 2002 36 21 29 12407573
2. Epidemiology of hepatitis C. Alter MJ, Hepatology 1997 26 62S 65S 10.1002/hep.510260711 9305666 (Pubitemid 27388074)
3. Hepatitis C virus biology. Giannini C, Brechot C, Cell Death Differ 2003 10 Suppl 1 27 38 12655344
4. Epidemiology of hepatitis C virus infection in Pakistan. Raja NS, Janjua KA, J Microbiol Immunol Infect 2008 41 4 8 18327420 (Pubitemid 351792115)
5. Case-control study of risk factors associated with hepatitis C virus infection among pregnant women in hospitals of Karachi-Pakistan. Khan UR, Janjua NZ, Akhtar S, Hatcher J, Trop Med Int Health 2008 13 754 761 10.1111/j.1365-3156.2008.02075.x 18384475 (Pubitemid 351678642)
6. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, et al. World J Gastroenterol 2009 15 5080 5085 10.3748/wjg.15.5080 19860002
7. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Raza SA, Clifford GM, Franceschi S, Br J Cancer 2007 96 1127 1134 10.1038/sj.bjc.6603649 17406349 (Pubitemid 46608308)
8. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM, J Virol 1994 68 5063 5073 7518529 (Pubitemid 24226574)
9. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Reed KE, Rice CM, Curr Top Microbiol Immunol 2000 242 55 84 10.1007/978-3-642-59605-6-4 10592656 (Pubitemid 29467521)
10. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, et al. Cancer Res 2001 61 4365 4370 11389061 (Pubitemid 32685760)
11. RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Liu M, Ding H, Zhao P, Qin ZL, Gao J, Cao MM, Luan J, Wu WB, Qi ZT, Biosci Biotechnol Biochem 2006 70 2049 2055 10.1271/bbb.60001 16960393 (Pubitemid 44451879)
12. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB, Zitzmann N, Proc Natl Acad Sci USA 2003 100 6104 6108 10.1073/pnas.1031527100 12719519 (Pubitemid 36576938)
13. Hepatitis C virus: an overview of current approaches and progress. Walker MA, Drug Discov Today 1999 4 518 529 10.1016/S1359-6446(99)01414-2 10529769 (Pubitemid 29497855)
14. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Bartenschlager R, Curr Opin Microbiol 2006 9 416 422 10.1016/j.mib.2006.06.012 16814596 (Pubitemid 44108723)
15. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. Idrees M, Riazuddin S, BMC Infect Dis 2008 8 69 10.1186/1471-2334-8-69 18498666 (Pubitemid 351803135)
16. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F, J Hepatol 2000 33 106 115 10.1016/S0168-8278(00)80166-X 10905593 (Pubitemid 30418941)
17. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. Koike K, Moriya K, J Gastroenterol 2005 40 329 336 10.1007/s00535-005-1586-z 15868369 (Pubitemid 40723928)
18. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R, J Hepatol 1995 22 449 456 10.1016/0168-8278(95)80108-1 7545199
19. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, Sutti S, Marrone A, Ruggiero G, Albano E, Adinolfi LE, J Hepatol 2008 48 399 406 10.1016/j.jhep.2007.10.011 18164507
20. Structural biology of hepatitis C virus. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM, Hepatology 2004 39 5 19 10.1002/hep.20032 14752815 (Pubitemid 38461460)
21. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K, Nat Med 1998 4 1065 1067 10.1038/2053 9734402 (Pubitemid 28417341)
22. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P, Gut 2004 53 1665 1672 10.1136/gut.2003.038364 15479690 (Pubitemid 39434113)
23. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA, Gastroenterology 2002 122 366 375 10.1053/gast.2002.30983 11832451 (Pubitemid 34116988)
24. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Chiarugi V, Magnelli L, Gallo O, Int J Mol Med 1998 2 715 719 9850741
25. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N, Clin Cancer Res 2001 7 1325 1332 11350902 (Pubitemid 32708688)
26. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT, Sung JJ, Int J Oncol 2004 24 853 860 15010822
27. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. Tang TC, Poon RT, Lau CP, Xie D, Fan ST, World J Gastroenterol 2005 11 1896 1902 15800977 (Pubitemid 40520983)
28. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T, Hepatology 2003 38 756 768 12939602 (Pubitemid 37052162)
29. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, Sawyers CL, Nat Rev Cancer 2002 2 489 501 10.1038/nrc839 12094235 (Pubitemid 37328931)
30. AKT plays a central role in tumorigenesis. Testa JR, Bellacosa A, Proc Natl Acad Sci USA 2001 98 10983 10985 10.1073/pnas.211430998 11572954 (Pubitemid 32928669)
31. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Assifi MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB, Am J Physiol Endocrinol Metab 2005 289 794 800 10.1152/ajpendo.00144.2005 15956049 (Pubitemid 41504378)
32. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. Waris G, Felmlee DJ, Negro F, Siddiqui A, J Virol 2007 81 8122 8130 10.1128/JVI.00125-07 17507484 (Pubitemid 47101498)
33. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL, J Clin Invest 1997 99 846 854 10.1172/JCI119248 9062341 (Pubitemid 27123620)
34. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Leone TC, Weinheimer CJ, Kelly DP, Proc Natl Acad Sci USA 1999 96 7473 7478 10.1073/pnas.96.13.7473 10377439 (Pubitemid 29299686)
35. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W, J Clin Invest 1999 103 1489 1498 10.1172/JCI6223 10359558
36. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. Pianko S, Patella S, Ostapowicz G, Desmond P, Sievert W, J Viral Hepat 2001 8 406 413 10.1046/j.1365-2893.2001.00316.x 11703571 (Pubitemid 35013565)
37. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. Cocquerel L, Wychowski C, Minner F, Penin F, Dubuisson J, J Virol 2000 74 3623 3633 10.1128/JVI.74.8.3623-3633.2000 10729138 (Pubitemid 30180306)
38. Hepatitis C virus, ER stress, and oxidative stress. Tardif KD, Waris G, Siddiqui A, Trends Microbiol 2005 13 159 163 10.1016/j.tim.2005.02.004 15817385 (Pubitemid 40463317)
39. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, Gonindard C, Alric L, Vinel JP, Pipy B, J Biol Chem 2001 276 23077 23083 10.1074/jbc.M100698200 11304537
40. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Mahmood S, Yamada G, Niiyama G, Kawanaka M, Togawa K, Sho M, Ito T, Sasagawa T, Okita M, Nakamura H, Yodoi J, Free Radic Res 2003 37 781 785 10.1080/1071576031000102141 12911275 (Pubitemid 36626438)
41. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, Kasai H, Cancer Res 1994 54 3171 3172 8205535 (Pubitemid 24208923)
42. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM, Gastroenterology 2002 122 352 365 10.1053/gast.2002.31001 11832450 (Pubitemid 34116987)
43. Processing and functions of Hepatitis C virus proteins. Suzuki R, Suzuki T, Ishii K, Matsuura Y, Miyamura T, Intervirology 1999 42 145 152 10.1159/000024973 10516468 (Pubitemid 29433581)
44. Oxidative damage and mitochondrial decay in aging. Shigenaga MK, Hagen TM, Ames BN, Proc Natl Acad Sci USA 1994 91 10771 10778 10.1073/pnas.91.23.10771 7971961 (Pubitemid 24349567)
45. E2 of hepatitis C virus inhibits apoptosis. Lee SH, Kim YK, Kim CS, Seol SK, Kim J, Cho S, Song YL, Bartenschlager R, Jang SK, J Immunol 2005 175 8226 8235 16339562 (Pubitemid 41798387)
46. Oxidative stress during viral infection: a review. Schwarz KB, Free Radic Biol Med 1996 21 641 649 10.1016/0891-5849(96)00131-1 8891667 (Pubitemid 26331094)
47. Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. Majano PL, Garcia-Monzon C, Lopez-Cabrera M, Lara-Pezzi E, Fernandez-Ruiz E, Garcia-Iglesias C, Borque MJ, Moreno-Otero R, J Clin Invest 1998 101 1343 1352 10.1172/JCI774 9525976 (Pubitemid 28166831)
48. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Mihm S, Fayyazi A, Hartmann H, Ramadori G, Hepatology 1997 25 735 739 10.1002/hep.510250340 9049227 (Pubitemid 27106462)
49. Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological severity of liver disease. Garcia-Monzon C, Majano PL, Zubia I, Sanz P, Apolinario A, Moreno-Otero R, J Hepatol 2000 32 331 338 10.1016/S0168-8278(00)80080-X 10707875 (Pubitemid 30093914)
50. Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in rat liver tumors induced by N-nitrosodiethylamine. Ahn B, Han BS, Kim DJ, Ohshima H, Carcinogenesis 1999 20 1337 1344 10.1093/carcin/20.7. 1337 10383909 (Pubitemid 29341458)
51. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ, Gastroenterology 2001 120 190 199 10.1053/gast.2001.20875 11208728 (Pubitemid 32061883)
52. Why there are two cyclooxygenase isozymes. Smith WL, Langenbach R, J Clin Invest 2001 107 1491 1495 10.1172/JCI13271 11413152 (Pubitemid 32574631)
53. Human cyclooxygenase-2 cDNA. Hla T, Neilson K, Proc Natl Acad Sci USA 1992 89 7384 7388 10.1073/pnas.89.16.7384 1380156
54. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM, J Biol Chem 1993 268 9049 9054 8473346 (Pubitemid 23118701)
55. Expression of cyclooxygenase- 2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Koga H, Sakisaka M, Ohishi T, Kawaquchi E, Taniquchi K, Sasatomi M, Harada T, Kusaba M, Tanaka R, Kimura Y, et al. Hepatology 1996 29 688 696
56. COX-2-a target for preventing hepatic carcinoma? Rahman MA, Kohno H, Nagasue N, Expert Opin Ther Targets 2002 6 483 490 10.1517/14728222.6.4.483 12223062
57. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Han C, Michalopoulos GK, Wu T, J Cell Physiol 2006 207 261 270 10.1002/jcp.20560 16331686
58. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E, Neoplasia 2001 3 53 61 10.1038/sj.neo.7900127 11326316 (Pubitemid 32201610)
59. Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Amano H, Haysahi I, Yoshida S, Yoshimura H, Majima M, Hum Cell 2002 15 13 24 10.1111/j.1749-0774.2002.tb00095.x 12126060
60. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J, Cardiovasc Res 2006 69 512 519 10.1016/j.cardiores.2005.09.019 16336951 (Pubitemid 43098807)
61. Role of AMP-activated protein kinase in mechanism of metformin action. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. J Clin Invest 2001 108 1167 1174 11602624 (Pubitemid 32995375)
62. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Tsujii M, DuBois RN, Cell 1995 83 493 501 10.1016/0092-8674(95)90127-2 8521479
63. The growing phospholipase A2 superfamily of signal transduction enzymes. Dennis EA, Trends Biochem Sci 1997 22 1 2 10.1016/S0968-0004(96)20031-3 9020581 (Pubitemid 27056087)
64. Regulation and inhibition of phospholipase A2. Balsinde J, Balboa MA, Insel PA, Dennis EA, Annu Rev Pharmacol Toxicol 1999 39 175 189 10.1146/annurev.pharmtox.39.1.175 10331081 (Pubitemid 29222556)
65. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Mayoral R, Fernandez-Martinez A, Bosca L, Martin-Sanz P, Carcinogenesis 2005 26 753 761 10.1093/carcin/bgi022 15661807 (Pubitemid 41214337)
66. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K, Hepatology 2002 35 1117 1124 10.1053/jhep.2002.32676 11981761 (Pubitemid 34454008)
67. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E, Gastroenterology 2001 121 1339 1347 10.1053/gast.2001.29691 11729113 (Pubitemid 33140451)
68. The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. Hope RG, Murphy DJ, McLauchlan J, J Biol Chem 2002 277 4261 4270 10.1074/jbc.M108798200 11706032 (Pubitemid 34968690)
69. Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C. Emerit I, Serejo F, Filipe P, Alaoui Youssefi A, Fernandes A, Costa A, Freitas J, Ramalho F, Baptista A, Carneiro de Moura M, Digestion 2000 62 200 207 10.1159/000007814 11025369
70. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, Rossi C, Mangia A, Negro F, J Hepatol 2005 42 744 751 10.1016/j.jhep.2004.12.034 15826725
71. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L, Gut 2005 54 1003 1008 10.1136/gut.2004.050302 15951550 (Pubitemid 40873917)
72. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Pekow JR, Bhan AK, Zheng H, Chung RT, Cancer 2007 109 2490 2496 10.1002/cncr.22701 17487861 (Pubitemid 46908652)
73. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla DC, Marcellin P, Vidaud M, Virology 2005 332 130 144 10.1016/j.virol.2004.11.009 15661146 (Pubitemid 40127235)
74. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R, J Hepatol 2002 37 837 842 10.1016/S0168-8278(02)00299-4 12445426 (Pubitemid 35404224)
75. Steatosis affects chronic hepatitis C progression in a genotype specific way. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F, Gut 2004 53 406 412 10.1136/gut.2003.018770 14960525 (Pubitemid 38241339)
76. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG, J Hepatol 2004 40 484 490 15123364 (Pubitemid 38230851)
77. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM, J Viral Hepat 2004 11 455 458 10.1111/j.1365-2893.2004.00528.x 15357652 (Pubitemid 39336228)
78. Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Halse R, Pearson SL, McCormack JG, Yeaman SJ, Taylor R, Diabetes 2001 50 1102 1109 10.2337/diabetes.50.5.1102 11334414 (Pubitemid 32374541)
79. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS, Nature 1997 389 610 614 10.1038/39335 9335502 (Pubitemid 27446179)